Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Vaxcyte, Inc.

PCVX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$61.92

▼ -5.72%

Market Cap $9.80B · Vol 732.88K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$9.80B

Mid Cap

Div Yield

N/A

EPS Growth

-47.72%

YoY

RSI (14)

46.19

Momentum

Beta

1.29

vs Market

52W High

$90.56

31.63% below

52W Low

$40.14

54.26% above

Volume

732.88K

Avg 931.27K

P/B

2.25

Price-to-book

ROE

-25.59%

Return on equity

Free Float

99.51%

Public shares

Shariah Compliance8 STANDARDS

✗ Vaxcyte, Inc. (PCVX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PCVX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.10%

-16.12%

+10.73%

+11.29%

YTD

+34.20%

+53.57%

+28.33%

+144.65%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-766,628,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-25.59%
ROA · ROIC	-23.54% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.25
P/FCF	N/A
EPS Growth	-47.72%
Outstanding Shares	152.20M

Technical Indicators

50-Day SMA	$61.65
200-Day SMA	$57.32
RSI (14)	46.19
Beta	1.29
52-Week High	$90.56
52-Week Low	$40.14

Volume Today	732.88K
Avg Daily Volume (30D)	931.27K
Relative Volume	0.79x
Volatility (10D)	55.36
Volatility (30D)	97.92
Free Float	99.51%

Analyst Consensus

BUY

Current Price $61.92

Mean Target $116.40

52W Low$40.14 52W High$90.56

Current

Target

$40.14 $90.56

Current Analyst target

+87.98% upside potential · 10 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG009PHHPP4

ISINUS92243G1085

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +3.34% ARGX.BR argenx SE +0.07% ARGX argenx SE -3.93% GMAB.CO Genmab A/S +1.59% GMAB Genmab A/S -4.32%

Company Profile

Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.